Former Savannah River Site workers can get help filing for health benefits
AIKEN, S.C. (WJBF) — Former Savannah River Site workers dealing with health issues can get help filing for benefits.
Nuclear Care Partners is helping workers file claims under the Energy Employees Occupational Illness Compensation Program. It covers cancers, neuropathy, hearing loss, and offers medical benefits plus a $150,000 lump sum for some diagnoses.
'If you have lung issues, you can't have your personal doctor say, you got COPD and let's file a claim and it go to the DOL. You need to see a pulmonologist who specializes in that,' Benefits Manager John Wall said. 'So that's kind of what we do is to try to push 'em in the right direction.'
For many, these benefits can be critical for covering medical costs. The risks at the Savannah River Site were substantial.
'You had a lot of radiation, different kinds, plutonium, uranium, different things out there,' he shared. 'You had people that worked there in the fifties, sixties and seventies and the early eighties that it's probably affected more than, a lot of others.'
Wall also shared a lot of people don't know about the 'white card.' It's a federal benefits card covering medical expenses for approved conditions. They can also get a physical every three years, paid for by the Department of Energy.
'There's so many people that have gone through these screening programs and found out that they had some kind of cancer of some type, and they caught it early enough to get it taken care of.'
Spouses and caregivers can also be compensated for in-home care.
'The DOL will pay them through our company, or pay us to pay them, for taking care of 'em, for cooking their bills, for cleaning help, cleaning up behind them for taking 'em to doctor appointments and things like that.'
There's another event on Thursday from 10 a.m. to 4 p.m. at Sweetwater Country Club in Barnwell.
You can also contact Nuclear Care Partners.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 hours ago
- Yahoo
Alpha-1 Antitrypsin Deficiency Market Research 2025-2035: Rising Demand for AATD Treatments Fuels Expansion with North America Leading
The global alpha-1 antitrypsin deficiency (AATD) market is expanding, driven by advances in diagnosis, treatment, and growing awareness. Key players like Grifols, CSL Behring, and Pfizer lead innovation. Market growth is fueled by rising disease prevalence and improved therapies but faces high costs. Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Treatment, Distribution Channel, and Regional Analysis - Analysis and Forecast, 2025-2035" report has been added to global alpha-1 antitrypsin deficiency (AATD) market is experiencing growth, fueled by advances in diagnosis, treatment options, and increasing awareness of the condition. AATD is a genetic disorder where the body produces insufficient alpha-1 antitrypsin, a protein that protects the lungs and liver. Its deficiency can lead to chronic obstructive pulmonary disease (COPD), emphysema, and liver cirrhosis. The condition often remains underdiagnosed, which presents an opportunity for early detection and primary treatment for AATD is augmentation therapy, which involves the infusion of AAT protein to restore deficient levels in the bloodstream. This therapy is designed to protect the lungs and slow the progression of emphysema. Other treatment options include symptomatic management, such as bronchodilators and corticosteroids. Research continues to explore gene therapies and novel treatments to better address the underlying genetic causes of market is expanding due to rising awareness about AATD, improvements in diagnostic tools, and innovations in treatment options. Key drivers include the increasing prevalence of the disease, particularly in older populations, and the growing availability of specialized therapies. However, challenges such as high treatment costs and the need for long-term care remain significant factors impacting the global alpha-1 antitrypsin deficiency market growth. The North America alpha-1 antitrypsin deficiency market is expected to lead globally due to advanced healthcare infrastructure, high awareness, and significant research investments. The market is primarily driven by augmentation therapy, which involves the administration of alpha-1 proteinase inhibitors to manage disease progression. Enhanced genetic testing and early diagnosis have improved treatment outcomes. Hospitals and specialty clinics serve as key treatment settings, offering specialized care. The region's favorable reimbursement policies and commitment to research and development further support market growth, positioning North America as a dominant force in the global alpha-1 antitrypsin deficiency treatment summary, the global alpha-1 antitrypsin deficiency market is poised for growth, with a strong focus on improving diagnostic accuracy and providing effective treatments, offering significant opportunities for stakeholders in the healthcare and pharmaceutical industries. How Can This Report Add Value to an Organization?Product/Innovation Strategy: Product launches and innovations in the global alpha-1 antitrypsin deficiency market are focused on advancing treatment options to improve patient care. These innovations aim to enhance the efficacy of therapies and streamline the detection and management of the disease. Key players in the global alpha-1 antitrypsin deficiency market, such as Grifols, CSL Behring, Takeda, GlaxoSmithKline plc, and Pfizer Inc., have been involved in offering of therapies for alpha-1 antitrypsin Strategy: Enterprises led by market leaders in the global alpha-1 antitrypsin deficiency market are continuously working on updating their product portfolios with innovative treatments to maintain competitiveness. A detailed competitive benchmarking of the key players in the global alpha-1 antitrypsin deficiency market has been conducted, providing insights into how these companies compare in terms of product offerings, market share, and innovation. This benchmarking provides readers with a clear understanding of the market landscape and the positions of the leading players. Additionally, comprehensive competitive strategies, such as partnerships, agreements, and collaborations, will help readers identify untapped revenue opportunities in the global alpha-1 antitrypsin deficiency Increasing demand for Alpha-1 Antitrypsin Deficiency therapies is anticipated to support the growth of the global alpha-1 antitrypsin deficiency market during the forecast period 2025-2035. The global alpha-1 antitrypsin deficiency market is expected to grow at a significant rate due to advancements in diagnostic technologies, the development of innovative therapies, and increasing awareness among patients and healthcare providers. Recent Developments: Regulatory Activities: In March 2025, Beam Therapeutics announced that the U.S. FDA cleared its Investigational New Drug (IND) application for BEAM-302, a base-editing therapy for AATD. This marks the first clinical advancement of a base-editing approach for AATD, with initial Phase 1/2 trial data showing promising results in correcting the PiZ mutation associated with the disease. Regulatory Activities: In February 2025, Grifols completed enrollment of the second cohort in its Phase 1/2 study for Alpha-1 15%, a subcutaneous AATD treatment. This development could provide patients with a more convenient administration option, enhancing treatment adherence and quality of life. Acquisition: In May 2024, Sanofi completed its acquisition of Inhibrx, Inc., gaining control of INBRX-101, a recombinant human AAT-Fc fusion protein under development for AATD treatment. INBRX-101 aims to normalize serum AAT levels with less frequent dosing, potentially offering a significant advancement in AATD therapy. Market Dynamics The following are the drivers for the global alpha-1 antitrypsin deficiency market: Increasing Awareness and Early Diagnosis Advancements in Treatment Options The global alpha-1 antitrypsin deficiency market is expected to face some limitations too, due to the following challenges: High Treatment Costs Limited Awareness in Emerging Markets Some of the prominent names established in this market are: Grifols CSL Behring Takeda Pharmaceuticals LFB Biotechnologies GlaxoSmithKline plc AstraZeneca Merck Pfizer Inc. Key Topics Covered: Executive SummaryScope and Definition1. Global Alpha-1 Antitrypsin Deficiency Market: Market Outlook1.1 Industry Outlook1.1.1 Market Overview and Ecosystem1.1.2 Market Trends1.1.3 Epidemiological Analysis of Alpha-1 Antitrypsin Deficiency1.1.3.1 By Region1.1.4 Clinical Trials1.1.4.1 By Phase1.1.4.2 By Sponsor Type1.1.5 Regulatory Landscape / Compliance1.1.5.1 Legal Requirement and Framework in the U.S.1.1.5.2 Legal Requirement and Framework in the E.U.1.1.5.3 Legal Requirement and Framework in Japan1.1.5.4 Legal Requirement and Framework in Rest-of-the-World1.2 Market Dynamics1.2.1 Impact Analysis1.2.2 Market Drivers1.2.3 Market Restraints1.2.4 Market Opportunities2. Global Alpha-1 Antitrypsin Deficiency Market, By Treatment, $Million, 2023-20352.1 Overview2.2 Augmentation Therapy2.3 Bronchodilators2.4 Corticosteroids2.5 Oxygen Therapy3. Global Alpha-1 Antitrypsin Deficiency Market, By Distribution Channel, $Million, 2023-20353.1 Overview3.2 Hospitals Pharmacy3.3 Retail Pharmacies3.4 Online Pharmacies4. Global Alpha-1 Antitrypsin Deficiency Market, By Region, $Million, 2023-20354.1 North America4.1.1 Key Findings4.1.2 Market Dynamics4.1.3 Market Sizing and Forecast4.1.3.1 North America Alpha-1 Antitrypsin Deficiency Market (by Distribution Channel)4.1.3.2 North America Alpha-1 Antitrypsin Deficiency Market (by Country)4.1.3.2.1 U.S.4.1.3.2.2 Canada4.2 Europe4.2.1 Key Findings4.2.2 Market Dynamics4.2.3 Market Sizing and Forecast4.2.3.1 Europe Alpha-1 Antitrypsin Deficiency Market (by Distribution Channel)4.2.3.2 Europe Alpha-1 Antitrypsin Deficiency Market (by Country)4.3 Asia-Pacific4.4 Rest-of-the-World5. Global Alpha-1 Antitrypsin Deficiency Market - Competitive Landscape and Company Profiles5.1 Competitive Landscape5.1.1 Growth Share Matrix (2024)5.1.1.1 By Treatment5.1.2 Key Strategies and Developments by Company5.1.2.1 Funding Activities5.1.2.2 Mergers and Acquisitions5.1.2.3 Regulatory Approvals5.1.2.4 Partnerships, Collaborations and Business Expansions5.1.3 Key Developments Analysis5.2 Company Profiles5.2.1 Company Overview5.2.2 Product Portfolio5.2.3 Target Customers/End Users5.2.4 Analyst View6. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
17 hours ago
- Yahoo
Sly Stone, 82, dies after 'prolonged battle' with COPD: Signs, symptoms and risk factors
Sly Stone, the funk icon and frontman of the group Sly and the Family Stone, has died. The 82-year-old musician's family confirmed the death of their "beloved dad" following a "prolonged battle" with COPD (chronic obstructive pulmonary disease) and undisclosed "underlying health issues." "Sly passed away peacefully, surrounded by his three children, his closest friend and his extended family,' the family's June 9 statement read. 'While we mourn his absence, we take solace in knowing that his extraordinary musical legacy will continue to resonate and inspire for generations to come.' This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Contact a qualified medical professional before engaging in any physical activity, or making any changes to your diet, medication or lifestyle. Stone, born Sylvester Stewart, helped pioneer a new sound of funk, pop and rock in the '60s, '70s' and '80s with hits like "Dance to the Music," "Sing a Simple Song" and "Everyday People." Stone and his band were inducted into the Rock & Roll Hall of Fame in 1993 and received a Lifetime Achievement Grammy Award in 2006. "His iconic songs have left an indelible mark on the world, and his influence remains undeniable." the family's statement continued. "In a testament to his enduring creative spirit, Sly recently completed the screenplay for his life story, a project we are eager to share with the world in due course, which follows a memoir published in 2024." Stone addressed his health issues in a 2023 interview with The Guardian. 'I have trouble with my lungs, trouble with my voice, trouble with my hearing and trouble with the rest of my body, too,' he said. Stone later added that his ailments, "haven't stopped me from hearing music, but they have stopped me from making it." What is COPD is it something you should worry about when it comes to your own health? Read on to learn more about COPD. COPD is a progressive lung disease that causes airways to become swollen and blocked. It's an umbrella term used to describe various lung conditions, including chronic bronchitis and emphysema, according to COPD Canada. In chronic bronchitis, the airways in your lungs become inflamed and narrowed. This means eventually, you will develop more mucus, leading to a persistent cough and difficulty breathing. For emphysema, the disease develops over time and involves the gradual damage of tiny air sacs in your lungs called alveoli. The damage eventually causes these air sacs to rupture, reducing the surface area that lets oxygen move through the bloodstream. The most common symptoms of COPD are difficulty breathing, chronic cough (sometimes with mucus) and feeling tired, according to the World Health Organization (WHO). The Canadian Lung Association added a person with COPD might also present some of the following symptoms: Feeling short of breath Lung infections (like the flu or pneumonia) that may last longer than they would in others Wheezing Losing weight without trying These symptoms can get worse quickly and may be called flare-ups. "These usually last for a few days and often require additional medicine," WHO stated. COPD develops over time, often as a result of a combination of risk factors, according to the WHO. These may include: Smoking or being exposed to second-hand smoke Exposure to dusts, fumes or chemicals in the workplace Indoor air pollution from sources like burning fuel for heat or coal to cook Asthma in childhood Early life events, including poor growth in utero, prematurity or frequent respiratory infections A rare genetic condition called alpha-1 antitrypsin deficiency The Canadian Lung Association indicated adults over age 40 who smoke or previously smoked may be at risk of COPD. "It is important to speak to a healthcare provider if you are at risk of COPD, even if you don't have symptoms or have only mild symptoms," the organization stated. "COPD is a progressive disease, meaning it gets worse over time." COPD is severely underdiagnosed, according to the health charity. That's because people living with the disease may not show any symptoms, or they link their symptoms to factors like age, a common respiratory infection or a "smoker's cough." Moreover, some people who have stopped smoking may believe they can no longer develop COPD. Historically, COPD was associated with older men who had a history of smoking. While the number of men and women who die of COPD in Canada each year is roughly equal, recent research has indicated COPD is likely underdiagnosed in women. The Canadian Lung Association shared women might also experience more severe symptoms and have earlier disease onset. Finally, over the past two decades, there has been a rising number of COPD hospitalizations for both women in the 40 to 64 age group as well as those older than 65. That's in addition to a decreasing number of hospitalizations in men. View this post on Instagram A post shared by Lung Health Foundation (@lunghealthfoundation) In Canada, one in four people will be diagnosed with COPD. There are more than two million Canadians impacted by the disease, and a further one million likely living with the condition unknowingly. COPD is also the second-leading cause of hospitalization in Canada, behind only childbirth. Globally, the WHO has indicated COPD is the third-leading cause of death, causing more than three million deaths in 2019 alone. That year, there were more than 212 million prevalent cases of COPD reported worldwide. There is no cure for COPD. Still, there are ways to improve the condition and possibly slow its progression. Since the majority of COPD cases are related to using cigarettes, it's best to never smoke — or stop smoking now. Moreover, you should speak to your supervisor about protection if you work around occupational exposure to chemical fumes, dusts or anything other elements that may increase your risk for COPD.
USA Today
a day ago
- USA Today
Sly Stone died after prolonged battle with COPD. The condition can be debilitating.
Sly Stone died after prolonged battle with COPD. The condition can be debilitating. Show Caption Hide Caption Health officials warn of highest whooping cough cases in a decade The Centers for Disease Control and Prevention is sounding the alarm about a spike in whooping cough cases in the United States. Straight Arrow News Sly Stone, an icon of funk music, has died at the age of 82 following a prolonged battle with COPD, a chronic lung condition that can block airflow and cause difficulty breathing. "It is with profound sadness that we announce the passing of our beloved dad, Sly Stone of Sly and the Family Stone," a statement shared with USA TODAY on June 9 reads. "After a prolonged battle with COPD and other underlying health issues, Sly passed away peacefully, surrounded by his three children, his closest friend, and his extended family." The statement continued: "While we mourn his absence, we take solace in knowing that his extraordinary musical legacy will continue to resonate and inspire for generations to come." Chronic obstructive pulmonary disease, or COPD, describes an ongoing group of lung conditions that includes chronic bronchitis and emphysema. It is the result of damaged lung tissue, which leads to inflammation that irritates the airway and limits airflow. Because such damage usually worsens over time, "COPD mostly affects people who are 50 or older," Dr. Shawn Aaron, senior scientist of the inflammation and chronic disease program at the Ottawa Hospital Research Institute in Canada, previously told USA TODAY. Here's what medical experts want you to know about COPD. Funk pioneer Sly Stone, leader of Sly and the Family Stone, dies at 82 What are the symptoms of COPD? Common symptoms of COPD include wheezing, chest tightness, a painful and persistent cough (with and without accompanying mucus) and fatigue. "Another of the most worrisome features of the disease can be periodic flare-ups, called exacerbations, which can greatly diminish your ability to breathe," Dr. Meilan King Han, pulmonary diseases specialist at University of Michigan Health, previously told USA TODAY. Due to the severity of such episodes, "some COPD patients can end up hospitalized," she added. COPD also makes people more vulnerable to respiratory infections, such as pneumonia, COVID-19 and tuberculosis. Related complications are why "COPD is a leading cause of death both in America and worldwide," Dr. David Mannino, chief medical officer at the COPD Foundation in Florida, previously told USA TODAY. At least 15 million adults have some form of COPD, per the U.S. Centers for Disease Control and Prevention, but Mannino said it could be twice that number, because the condition often goes misdiagnosed or undiagnosed. What causes COPD? The damaged lung tissue associated with COPD is most often caused by long-term exposure to irritants, such as fumes, dust, chemicals or smoke. This is why "cigarette smoke is the main cause of COPD in high-income countries like the United States," Mannino said. "However, not everyone who smokes will develop COPD symptoms, and not all people with COPD have a history of smoking." Indeed, some 25% of people with COPD have never smoked a cigarette. COPD can be debilitating. What exactly is it? "Exposure to outdoor pollution or indoor cooking smoke and fumes is a major cause of COPD," said Aaron, especially in developing countries. He added that some people also develop the condition because of poor early lung development related to premature birth. Genetic factors, early-life respiratory infections and a history of asthma "can all also contribute to the development of COPD," Han said. How is COPD treated? Regardless of what's causing the condition, COPD is treatable. "The mainstays of therapy have historically been inhaled bronchodilators and inhaled steroids," according to Han. Such medications can reduce breathlessness, improve stamina and lower one's risk of flare-ups, Mannino said. He added that non-pharmacologic therapies are also helpful in reducing symptoms and risk of flare-ups. "These include participating in pulmonary rehabilitation, using oxygen therapy as prescribed and adhering to vaccination guidelines," he said. And you can't overemphasize the importance of quitting smoking, added Aaron. "By adhering to medication recommendations, avoiding infection and irritating fumes, eating foods that support lung health and strengthening lung tissue by getting plenty of cardiovascular activity," said Mannino, "individuals with COPD can maintain a good quality of life." Contributing: Daryl Austin and Marco della Cava
